ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Recruiting

Phase 2

ASTX727 & DasatinibASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT05007873

Conditions

Chronic Phase Chronic Myelogenous Leukemia

Philadelphia Chromosome Positive

BCR-ABL1 Positive Chronic Myelogenous Leukemia

BCR-ABL1 Positive

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Dasatinib

Decitabine and Cedazuridine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-17. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2025-03-03.